Oxolin

Quick links to important sections

Oxolin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxolin

What is Oxolin?

Property Description
Active ingredient Oxolinic Acid
Form Ointment (Topical), Tablet (Oral - historical/international)
Pharmacological class First-Generation Quinolone Antibiotic
Common use Anti-infective / Antibacterial
Origin Synthetic

Oxolin is a medicinal preparation whose therapeutic properties are derived from its sole active ingredient, Oxolinic Acid. This compound is a synthetic chemical substance, not naturally sourced, and is the core component that defines the drug's action. The product is defined as a single-ingredient agent, designed to function as an anti-infective. It has been prepared in various dosage forms, most recognizably as an ointment for topical application, utilizing an oleaginous/lipid base. The availability of other historical and international forms, such as oral tablets, means the method of administration depends entirely on the formulation.

Oxolin is definitively classified as a synthetic antibacterial agent belonging to the first-generation quinolone antibiotic class. It is categorized under the Anatomical Therapeutic Chemical (ATC) Classification System code J01MB05, within the group "Other quinolones." This classification confirms its role as one of the original synthetic agents developed to target susceptible bacteria.

This classification establishes the drug's general purpose: to function as a powerful anti-infective by exerting a bactericidal action against susceptible organisms. The mechanism involves disrupting the ability of bacterial cells to manage their genetic material, which prevents them from reproducing. Oxolinic Acid acts as a DNA gyrase inhibitor, characteristic of this antibiotic class. This mechanism explains that the medicine works by directly interfering with the systems bacteria need to survive and multiply, a property clinically recognized for its effectiveness in situations requiring elimination of bacterial growth. Its status as a first-generation agent is a differentiating factor, as it precedes and contrasts with the later fluoroquinolones in chemical structure and spectrum.

What side effects are possible with Oxolin?

Oxolinic Acid, classified as a first-generation quinolone antibiotic, has a safety profile that is defined by official regulatory documentation. Adverse reactions are grouped by System-Organ Class, with primary concerns related to the Nervous System and the Musculoskeletal System, alongside effects on the Immune System and Gastrointestinal System.

Officially listed reactions include psychiatric and nervous system disturbances such as nervous excitation, insomnia, tremor, and confusion. The regulatory labeling details the potential for serious adverse reactions, which include the risk of tendon rupture and peripheral neuropathy (nerve damage). Other serious events documented for the class are seizures, toxic psychosis, increased intracranial pressure, and severe, potentially fatal anaphylactoid reactions, as well as Clostridium difficile-associated diarrhea.

Specific safety considerations apply to certain populations. Caution is advised for older adults (particularly when using corticosteroids) and for individuals with pre-existing conditions such as seizure disorders or hepatic/renal impairment. The safety profile also mandates avoidance of excessive sunlight exposure due to the risk of phototoxicity and requires periodic monitoring of blood counts and organ function for treatment extending beyond two weeks. Some severe reactions, such as tendon injuries, may be reported months after treatment cessation.

Overdose and Emergency Response

Oxolin Overdose and When to Seek Help

Oxolin (Oxolinic acid) is a quinolone antibiotic primarily used in veterinary and fish farming applications. It is not a pharmaceutical agent approved for human use by major governmental regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).


Overdose Scope and Guidance

Due to its classification and limited use in human medicine, there is no standardized, officially documented overdose profile from major human health regulatory documents for Oxolin (Oxolinic acid). The lack of a human-approved label means there are no formal, regulator-mandated statements on overdose presentations or required emergency actions.

Overdose presentations and symptoms for related antibiotic compounds (quinolones/fluoroquinolones) may include central nervous system (CNS) effects such as seizures, tremors, and severe headache, as well as potential cardiovascular irregularities. Additionally, high doses of related compounds are associated with blood cell abnormalities and sudden weakness.

Overdose Indicator Regulatory Basis/Status
Documented Presentations None in major human regulatory documents.
Emergency-Response Actions Not officially stated in human drug labeling.

When Immediate Medical Help is Required

Any ingestion of a dose significantly higher than prescribed (if an off-label prescription was issued) or any accidental consumption should be treated as a medical emergency. Immediate medical attention is required if the following symptoms occur, based on the general class of drug:

  • Seizures or convulsions
  • Severe or persistent headache
  • Sudden weakness or loss of consciousness
  • Rapid and/or irregular heartbeat

Contact emergency services immediately and inform them of the substance and the amount taken. Expert guidance from a poison control center should be sought without delay. Due to the high potential for serious toxicity with overdose of this drug class, a medical professional must manage the situation.

Therapeutic Uses of Oxolin

Oxolin is commonly used across therapeutic domains involving certain distressing symptoms and applied in clinical contexts where supportive symptom management is appropriate. The medication is relevant for easing symptoms associated with conditions like acute viral rhinitis, seasonal exposure scenarios, and certain localized viral skin manifestations.

Symptomatic Relief and Contextual Support

Oxolin is relevant for managing symptom clusters that may become intense or disruptive in the nasal passages, such as symptoms related to inflammatory or irritative states. It contributes to easing the overall symptom load during symptomatic phases.

“The use of the medication is relevant when symptoms interfere with daily functioning. It may assist with maintaining functional stability and supports patients during difficult episodes by easing distress.”

It may assist with managing symptoms that become more noticeable during acute or episodic changes. It is relevant for easing certain distressing symptoms associated with localized viral skin manifestations. This is applied in addressing conditions where symptoms lead to temporary functional strain or discomfort in the affected area, and may be part of supportive symptom management.


Quick Fact: Symptomatic Support for Viral Manifestations

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxolin?

Eligibility to use Oxolin (Oxolinic Acid) is strictly governed by regulatory documentation based on its classification as a first-generation quinolone antibiotic. This information defines which populations are absolutely excluded and which require special caution.


Absolute Contraindications

Use is formally contraindicated (must not be used) in several patient groups, as defined in official labeling for the quinolone class:

  • Infants less than three months of age.
  • Patients with a history of convulsive disorders (e.g., epilepsy).
  • Patients with porphyria.
  • Individuals with known hypersensitivity to Oxolinic Acid or related compounds.

Restricted and Conditional Use

Some populations require special caution due to an elevated risk profile or insufficient data:

  • Age-Related: Use in older adults requires caution due to a higher risk of specific class-wide effects.
  • Organ Function: Special caution is required for patients with renal impairment (kidney disease) or hepatic impairment (liver disease).
  • Physiological States: Use is generally not recommended during pregnancy due to limited data and is restricted during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the active ingredient, Oxolinic Acid, establishes specific interaction patterns, primarily in the pharmacokinetic and pharmacodynamic domains.

Pharmacokinetic Interactions

Oxolinic Acid is documented as an inhibitor of the cytochrome P450 1A2 (CYP1A2) enzyme. This metabolic interaction may reduce the clearance and increase the systemic exposure of co-administered medicines that are substrates of CYP1A2. Separately, the active ingredient forms chelates with divalent and trivalent metal ions, such as aluminum, magnesium, iron, and zinc. This chelation process reduces the absorption of Oxolinic Acid from the gastrointestinal tract, potentially lowering its serum concentration and systemic exposure.

Administration restrictions apply to prevent this reduced absorption: Oxolinic Acid should be administered at least two hours before or after Antacids containing aluminum or magnesium.

Pharmacodynamic and Exposure Effects

Co-administration with certain Penicillins, specifically Ampicillin and Amoxicillin, may officially increase the serum concentration of Oxolinic Acid. Furthermore, official warnings exist regarding the pharmacodynamic potentiation when combined with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aminophenazone, Antipyrine, and Antrafenine. This combination is documented to increase the risk of neuroexcitatory activities.

Mechanism of Action

Targeting the Bacterial Genetic Machinery

Oxolinic Acid’s mechanism involves the inhibition of essential bacterial enzymes, primarily DNA Gyrase (Topoisomerase II), specifically the GyrA subunit. The drug acts as a competitive inhibitor that binds to the enzyme, trapping it while it is bound to the bacterial DNA. This interaction obstructs the enzyme’s normal function of managing DNA supercoiling, which is critical for replication and transcription.


Mechanistic Cascade to Bactericidal Action

By stabilizing the enzyme in the complexed state, Oxolinic Acid acts as a "poison" that causes DNA double-strand breaks (DSBs). This sequence leads directly to the bactericidal action, resulting in the death of the susceptible bacterial cell. The drug’s mechanism is constrained by adaptive bacterial mechanisms, such as mutations in the target enzyme genes or the overexpression of efflux pumps that actively expel the drug from the cell, restricting the formation of the DNA-Gyrase complex.

Dosage and Administration Information

Oxolin (Oxolinic acid) is a quinolone-class antibacterial agent used primarily in veterinary medicine. It is not approved for human use by major regulatory bodies. Official instructions for its use are established for specific animal species in regions where it is authorized, outlining a precise administration protocol.

Official Administration Guidelines

Administration Scope Specification
Route of Administration Oral (via medicated feed, drinking water, or as a bolus)
Dosing Schedule Weight-based (e.g., 12 mg/kg body weight/day for fish, 20 mg/kg body weight/day for calves, pigs, and poultry)
Frequency and Timing Administered daily in feed or water
Duration of Use Time-limited (e.g., up to 7 days for fin fish; up to 5 days for pigs and poultry; up to 10 days for calves)

Procedural Structure

The official instructions mandate that the exact dose be calculated based on the weight of the animal (the specific age-group rule) and administered by the oral route as a component of their daily feed or water. This daily dosing must be maintained continuously for the defined duration of use, such as up to 7 days. This structure standardizes the application method and dosage for the authorized species.

Recent Clinical Evidence

Research evidence / Overview of Studies for Oxolin (Oxolinic Acid)

Evidence for Use as a Historical Antibacterial Agent

Oxolinic Acid was studied for its action as a first-generation quinolone antibiotic. The research landscape includes historical Randomized Controlled Trials (RCTs) and Comparative Clinical Trials that examined its use for certain bacterial infections like urinary tract infections. These early studies primarily monitored standard anti-infective outcomes, such as bacterial eradication rates and clinical cure rates, in populations mainly consisting of adults with acute urinary tract infections (UTIs).

Findings from this foundational research describe patterns observed in the laboratory setting, where its activity was studied against specific susceptible bacteria, which aligns with its official classification. Clinical reports from the time describe patterns observed during its use for infections and served as the basis for its historical classification in this therapeutic area. The data contributes to the broader evidence landscape by describing the drug's activity as a single-ingredient antibacterial agent.

Evidence for Use in Symptom Management of Acute Viral Rhinitis

The topical use of the ointment was studied for conditions characterized by episodic or acute manifestations, such as symptoms of acute viral rhinitis. The research available for this application includes observational studies and small-scale clinical trials which evaluated its use on the nasal passages. Studies in this context focused on episodes where symptoms become more noticeable and examined outcomes describing perceived discomfort, such as changes in symptom load or the overall duration of symptoms.

These studies report how symptoms evolved in the observed populations over defined time intervals, which were generally short-term (days). Findings describe patterns observed in the studies related to symptoms of distress associated with inflammatory or irritative states. This research provides insight into short-term changes in outcomes related to physical discomfort during periods of increased symptom activity.

What is Still Uncertain About the Research for Oxolin

The certainty surrounding the evidence remains low for the non-antibacterial, symptomatic applications due to reliance on modest sample sizes and study designs that are often observational. Comparative evidence is lacking in modern trials that assess the topical ointment against standard supportive care. Long-term effects are not fully established across any of the indications studied. Finally, the research provides context but not individual predictions regarding how any specific patient will respond, and research is ongoing in the broader class of compounds.

Key Studies & References ATC/DDD Index 2024: J01MB05 Oxolinic acid (WHO Collaborating Centre for Drug Statistics Methodology)

Frequently Asked Questions (FAQ)

Common questions about Oxolin (FAQ)


Q: How quickly does Oxolin start to work after application?

Official regulatory documents do not explicitly state the specific time it takes for the topical application of the ointment to begin working. However, studies on the systemic (internal) absorption of the active ingredient, Oxolinic Acid, show that peak concentrations in the body were observed in under one hour after oral administration in authorized animal species.


Q: How long can you use Oxolin continuously?

For the active ingredient, Oxolinic Acid, official regulatory guidelines related to its approved veterinary uses require administration to be time-limited, typically no more than 7 to 10 days. Official documentation does not specify a maximum continuous duration for the non-approved topical use in humans.


Q: Does Oxolin interact with common over-the-counter pain relievers?

Official warnings describe a potential increased risk of neuroexcitatory activities when Oxolinic Acid is combined with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), specifically naming Aminophenazone, Antipyrine, and Antrafenine. Regulatory information does not explicitly address interactions with other common over-the-counter pain relievers.


Q: Are there any known drug interactions with birth control pills and Oxolin?

Regulatory documents state that the active ingredient, Oxolinic Acid, is an inhibitor of the CYP1A2 enzyme, which is a key mechanism for processing many drugs. This may affect the metabolism of certain co-administered drugs that rely on the CYP1A2 enzyme for breakdown, but official drug labels do not contain an explicit warning regarding oral contraceptives.


Q: Is there a risk of developing a resistance to Oxolin over time?

Yes, official mechanism of action texts note that the antibacterial effects of Oxolinic Acid can be constrained by adaptive changes in bacteria. This includes the development of resistance mechanisms like mutations in the target DNA enzyme or the overexpression of efflux pumps, which actively remove the drug from bacterial cells.


Q: Why do some people call Oxolin an 'interferon inducer'?

The official classification for Oxolinic Acid, established by health authorities, identifies it as a first-generation quinolone antibiotic that acts primarily as a DNA Gyrase inhibitor. The term 'interferon inducer,' which relates to stimulating the body's immune response, is not listed in the product's official pharmacological classification or mechanism of action.


Q: Do you need a prescription to buy Oxolin?

In regions where Oxolinic Acid is officially authorized for animal use, its administration is regulated under veterinary oversight, often requiring a prescription or Veterinary Feed Directive. Its status for human topical use varies by country; however, quinolone antibiotics are generally subject to strict regulatory control.


Q: Is there a nasal spray form of Oxolin available?

No. The official dosage forms listed in regulatory documents for Oxolinic Acid are the ointment (for topical use) and, historically or internationally, an oral tablet. A nasal spray formulation is not listed among the recognized dosage forms.


Q: Are there different strengths or concentrations of Oxolin?

Yes, official information indicates that Oxolin has been prepared in various concentrations and dosage forms. The ointment is most commonly available at a low concentration (e.g., 0.25%), while other forms or regional products may utilize different concentrations (e.g., 3%).


Q: Is Oxolin safe for elderly people?

Official regulatory labeling advises that caution is specifically required when using the product in older adults. This regulatory caution is advised due to the potential for a greater susceptibility to certain side effects associated with the quinolone class in this population, particularly when corticosteroids are also being used.


Q: What color is Oxolin ointment supposed to be?

While regulatory specifications describe the active ingredient, Oxolinic Acid, as a white or off-white powder, the final color of the ointment formulation is not always explicitly defined on all product labels. The color typically reflects the properties of the active substance and the base used.


Q: Is Oxolin considered a homeopathic or conventional medicine?

Oxolin is classified as a conventional, synthetic antibacterial agent. Its official categorization by the World Health Organization (ATC code J01MB05) places it firmly within the class of first-generation quinolone antibiotics, which are chemically synthesized drugs.


Q: Is Oxolin safe to use while breastfeeding?

Official regulatory guidance states that the use of Oxolinic Acid is generally restricted during lactation (breastfeeding). This restriction is typically in place due to limited available data to confirm its safety in this population.


Q: How do I know if I am allergic to an ingredient in Oxolin?

The official drug labeling specifies that the product is formally contraindicated, meaning it must not be used, if a patient has a known hypersensitivity (allergy) to Oxolinic Acid or any related compounds within the quinolone class.


Q: Are there different forms of Oxolin for internal versus external use?

Yes, the product has been prepared in formulations intended for different routes of administration. It has been available as an ointment intended for topical (external) use, and historically or internationally, as an oral tablet designed for internal use.


How should Oxolin be stored and disposed of?

Official Storage and Disposal Requirements

Oxolin ointment must be stored according to regulatory specifications to maintain its stability and effectiveness, as documented by health authorities.

Storage Category Requirement
Temperature Control Store in a cool place, typically between 2 C and 8 C (36 F and 46 F), and do not freeze.
Environmental Protection The container must be kept tightly closed in a dry place and protected from light.
Child Safety The medicine must be kept out of the sight and reach of children.

Expired or unused Oxolin must be managed as pharmaceutical waste. Official instructions require that the product not be disposed of in drains or wastewater to prevent environmental contamination. Disposal must comply with local or national regulations, often requiring submission to a drug take-back program or following specific FDA guidance for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxolin found in:

A-Z Index: